RPRX$66.520.98%-0.66
After Hours: 66.520.00 0.00%
Royalty Pharma Plc (RPRX)
Date: 2026-11-02 16:00O: 66.97H: 67.10L: 66.43C: 66.52Vol: 2.071M
Royalty Pharma Plc stock is traded at $66.52, with a volume of 2,071,391. It is down -0.98% in the last 24 hours and up +16.38% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Previous Close:
$67.18
Open:
$66.97
24h Volume:
2,071,391
Relative Volume:
0.66
Market Cap:
$29.62B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
34.84
EPS:
$1.91
Net Cash Flow:
$574.14M
1W Performance:
+2.72%
1M Performance:
+16.38%
6M Performance:
+34.47%
1Y Performance:
+77.20%
1-Day Range:
$66.43$67.10
1-Week Range:
$63.49$67.71
52-Week Range:
$36.03$67.71
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma PlcSector
HealthcareIndustry
BiotechnologyPhone
(212) 883-0200Address
110 EAST 59TH STREET, NEW YORK, NY, USACompare RPRX vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|
RPRX Royalty Pharma Plc | $29.62B | $2.54B | $815.00M | $574.14M | $1.91 |
 VRTX Vertex Pharmaceuticals Inc | $140.94B | $12.59B | $4.41B | $3.80B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $99.46B | $16.90B | $4.82B | $3.83B | $41.04 |
 MRNA Moderna Inc | $88.17B | $2.23B | -$3.15B | -$1.24B | -$8.15 |
 ARGX Argen X Se Adr | $55.03B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $40.86B | $6.13B | $655.71M | $1.33B | $4.48 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
Royalty Pharma Plc Stock (RPRX) Financials Data
Royalty Pharma Plc Stock (RPRX) Insider Trading
- Urist MarshallOct 05 '26EVP, Research & Investments
- Transaction
- Sale
- Cost
- $57.10
- #Shares
- 4,126
- Value ($)
- 235,595
- #Shares Total
- 0
- Urist MarshallOct 05 '26Officer
- Transaction
- Proposed Sale
- Cost
- $57.10
- #Shares
- 4,126
- Value ($)
- 235,595
- #Shares Total
- 0
- Urist MarshallSep 28 '26EVP, Research & Investments
- Transaction
- Sale
- Cost
- $57.88
- #Shares
- 4,126
- Value ($)
- 238,813
- #Shares Total
- 4,126
- Urist MarshallSep 28 '26Officer
- Transaction
- Proposed Sale
- Cost
- $57.88
- #Shares
- 4,126
- Value ($)
- 238,813
- #Shares Total
- 0
- Hite ChristopherSep 22 '26EVP & Chairman, Partnering
- Transaction
- Sale
- Cost
- $58.53
- #Shares
- 100,000
- Value ($)
- 5,853,095
- #Shares Total
- 270,401
- SCH Investment Partners LLCSep 22 '26Officer
- Transaction
- Proposed Sale
- Cost
- $58.47
- #Shares
- 100,000
- Value ($)
- 5,846,972
- #Shares Total
- 0
- SCH Investment Partners LLCAug 18 '26Officer
- Transaction
- Proposed Sale
- Cost
- $60.12
- #Shares
- 100,000
- Value ($)
- 6,012,000
- #Shares Total
- 0
- Hite ChristopherAug 18 '26EVP & Chairman, Partnering
- Transaction
- Sale
- Cost
- $59.97
- #Shares
- 100,000
- Value ($)
- 5,997,250
- #Shares Total
- 370,401
- Terrance CoyneAug 13 '26Officer
- Transaction
- Proposed Sale
- Cost
- $58.56
- #Shares
- 11,002
- Value ($)
- 644,277
- #Shares Total
- 0
- Coyne Terrance P.Aug 13 '26EVP & CFO
- Transaction
- Sale
- Cost
- $58.68
- #Shares
- 11,002
- Value ($)
- 645,551
- #Shares Total
- 0
